Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,866 | -66,539 | -22,463 | -16,985 | -11,402 |
| Depreciation Amortization | 2,813 | 11,975 | 8,932 | 5,872 | 2,884 |
| Income taxes - deferred | -183 | 33,557 | -5,019 | -2,392 | -336 |
| Accounts receivable | 9,645 | 368 | 6,514 | 7,101 | 6,449 |
| Accounts payable and accrued liabilities | 390 | 448 | 1,757 | 1,169 | 410 |
| Other Working Capital | 8,998 | -4,794 | -1,319 | 2,244 | 3,029 |
| Other Operating Activity | -5,533 | 20,299 | 7,683 | 2,974 | -1,159 |
| Operating Cash Flow | $-2,736 | $-4,686 | $-3,915 | $-17 | $-125 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -24,884 | 14,056 | 15,059 | -4,517 | 10,270 |
| PPE Investments | -2,162 | -3,832 | -3,026 | -2,370 | -816 |
| Purchase Sale Intangibles | -33 | -106 | -74 | -76 | -2 |
| Other Investing Activity | -33 | -107 | -74 | -74 | -2 |
| Investing Cash Flow | $-27,079 | $10,117 | $11,959 | $-6,961 | $9,452 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,068 | 5,582 | 4,166 | 2,075 | 690 |
| Debt Repayment | -869 | -4,745 | -1,805 | -1,660 | -1,518 |
| Common Stock Issued | 21 | 325 | 240 | 103 | 39 |
| Common Stock Repurchased | 0 | -13,925 | -14,405 | -14,434 | -10,627 |
| Other Financing Activity | -239 | -669 | -402 | -231 | -129 |
| Financing Cash Flow | $3,981 | $-13,432 | $-12,206 | $-14,147 | $-11,545 |
| Exchange Rate Effect | 646 | 109 | -1,303 | -2,149 | -1,228 |
| Beginning Cash Position | 90,853 | 98,745 | 98,745 | 98,745 | 98,745 |
| End Cash Position | 65,665 | 90,853 | 93,281 | 75,470 | 95,299 |
| Net Cash Flow | $-25,188 | $-7,892 | $-5,465 | $-23,275 | $-3,446 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,736 | -4,686 | -3,915 | -17 | -125 |
| Capital Expenditure | -2,168 | -4,084 | -3,083 | -2,426 | -849 |
| Free Cash Flow | -4,904 | -8,770 | -6,998 | -2,443 | -974 |